Mechanism of action EGFR is a transmembrane protein.<unk>  works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor. Pharmacokinetics The pharmacokinetics (PK) of<unk>  shows the so-called target-mediated disposition behavior. However, the PK is approximately linear at clinical doses, and the terminal half-life for a typical male patient of 80 kg and 60 years of age with colorectal cancer is about 9.4 days.
Panitumumab
Necitumumab
Cetuximab
Sorafenib
Dasatinib
Neratinib
Fostamatinib
Tucatinib